

to identify patients diagnosed with ovarian cancer and were taking treatment from January 2001 to December 2013 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan at least for a year. Descriptive statistics and chi-square tests were performed on the data. **RESULTS:** There were a total of 2,562 patients that met the study inclusion criteria. There were 1,718 (67.10%) patients <65 years of age (adult) and 844 (32.90%) ≥ 65 years of age (geriatric). There was a significant difference ($p < 0.05$) between the mean ages of two groups (52.48 ± 9.76 vs 73.08 ± 6.62 years). The mean length of stay of adult patients was lower than ($p < 0.05$) geriatric patients (1.23 ± 1.57 vs 1.45 ± 2.67 days). There were more patients in adult group in the East (23.5% vs 21.0%) and MidWest (30.3% vs 27.6%) regions but no significant difference was found ($p > 0.05$). On average, patients were continuously enrolled in the same health plan for 62.00 ± 37.03 vs 66.64 ± 35.21 months and submitted 567.10 ± 574.49 vs 740.58 ± 629.71 claims with a significant difference ($p < 0.05$) between the two groups. Patients on average were charged by the provider $\$533.62 \pm 2232.26$ vs $\$492.09 \pm 2123.24$ for their ovarian cancer treatment ($p < 0.05$) during the study period. However, the actual paid amount by the health plan was $\$225.25 \pm 1215.97$ vs $\$136.79 \pm 962.99$ with a significant difference between the groups ($p < 0.05$). **CONCLUSIONS:** The majority of the patients were <65 years of age and were paid higher amount by the health plan for the treatment of ovarian cancer.

PCN287

PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH PROSTATE CANCER

Greene N¹, Greene M²¹MCPhS University, Medford, MA, USA, ²Georgia State University, Medford, MA, USA

OBJECTIVES: The objective of this study is to assess the characteristics and health care resource utilization of patients diagnosed with prostate cancer. **METHODS:** A large US administrative retrospective claims database was used to identify patients diagnosed with prostate cancer and were taking treatment in the USA from January 2001 to December 2013 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan at least for a year. Descriptive statistics and chi-square tests were performed on the data. **RESULTS:** There were a total of 19,279 patients that met the study inclusion criteria. Of these, 6,359 (33.0%) patients were <65 years of age (adult) and 12,920 (67.0%) ≥ 65 years of age (geriatric). There was a significant difference ($p < 0.05$) in the mean ages of two groups (59.02 ± 4.99 vs 74.55 ± 6.55 years). There were more patients in adult group in the MidWest (28.5% vs 23.6%) and South (38.3% vs 36.4%) regions with a significant difference between the groups ($p < 0.05$). On average, patients were continuously enrolled in the same health plan for 65.37 ± 35.91 vs 65.80 ± 32.84 months ($p > 0.05$) and submitted 366.85 ± 381.92 vs 492.37 ± 431.42 claims during the study period ($p < 0.05$). Patients on average were charged by the provider $\$763.84 \pm 3003.48$ vs $\$595.56 \pm 2207.71$, the allowed amount by the health plan was $\$343.75 \pm 1496.33$ vs $\$270.81 \pm 1380.54$ and the actual paid amount by the health plan was $\$309.67 \pm 1294.90$ vs $\$165.08 \pm 768.48$ with a significant difference between the groups ($p < 0.05$). **CONCLUSIONS:** The majority of the patients were geriatric. On average, geriatric patients were charged less by the provider and actual paid amount by the health plan was less compared to adult patients for the treatment of prostate cancer.

PCN288

ABSTRACT TITLE: DESCRIPTIVE EVALUATION OF PATIENT CHARACTERISTICS AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS DIAGNOSED WITH MALIGNANT NEOPLASM OF RECTUM

Greene N¹, Greene M²¹MCPhS University, Medford, MA, USA, ²Georgia State University, Medford, MA, USA

OBJECTIVES: The objective of this study is to assess the characteristics and health care resource utilization of patients diagnosed with malignant neoplasm of rectum. **METHODS:** A large US administrative retrospective claims database was used to identify patients diagnosed with malignant neoplasm of rectum and were taking treatment in the USA from January 2001 to December 2013 were included in the study. All patients were ≥ 18 years of age and continuously enrolled in the same health plan at least for a year. Descriptive statistics and chi-square tests were performed on the data. **RESULTS:** There were a total of 2,461 patients that met the study inclusion criteria. Of these, 1,695 (68.87%) were <65 years of age (adult) and 766 (31.13%) were ≥ 65 years of age (geriatric). There was no difference ($p > 0.05$) in the distribution of males (57.2% vs 57.0%) and a significant difference ($p < 0.01$) between the mean ages of two groups (53.49 ± 7.50 vs 72.73 ± 5.26 years) was found. The mean length of stay between the groups (1.96 ± 4.37 vs 1.96 ± 4.56 days) was almost same. There were more patients in adult group in the East (31.3% vs 22.7%) and South (38.3% vs 37.3%) regions with a significant difference ($p < 0.05$) between the groups. On average, patients were continuously enrolled in the same health plan for 63.50 ± 36.74 vs 64.43 ± 32.40 months and submitted 640.33 ± 580.25 vs 680.26 ± 598.82 claims with no significant difference ($p > 0.05$) between the two groups. Patients on average were charged by the provider $\$611.69 \pm 2771.24$ vs $\$639.36 \pm 3554.90$ ($p > 0.05$), allowed amount by the health plan was $\$284.71 \pm 1515.83$ vs $\$287.31 \pm 1996.25$ ($p > 0.05$) and the actual paid amount by the health plan was $\$268.84 \pm 1490.76$ vs $\$145.21 \pm 1068.87$ ($p < 0.05$). **CONCLUSIONS:** The majority of the patients were adult and health plans paid higher amount for these patient groups compared to geriatric patients for the treatment of malignant neoplasms of rectum.

PCN289

INTERNATIONAL DIFFERENCES IN THE ROLE OF PAYER AND ADMINISTRATIVE CONTROLS IN PRESCRIBING DECISIONS

Silvey M, Rider A, Wellam HW, Piercy J

Adelphi Real World, Bollington, UK

OBJECTIVES: To assess the extent to which prescribing decisions are influenced by payer implemented controls. **METHODS:** Data were drawn from the Adelphi Disease Specific Programme (DSP) in Multiple Myeloma conducted in Q1 2015. DSPs are cross sectional surveys of physicians and their consulting patients. Fifty Haematologists/

Haematological-oncologists in each of France, Germany, Italy, Spain and the UK, actively managing patients with Multiple Myeloma, were asked to complete patient record forms (PRF) prospectively for the next eight patients who consulted their clinic. In addition to clinical considerations, prescribers were asked to record the impact of administrative controls on their prescribing decisions as well as being asked attitudinal and perceptual information on the influence of payer recommendations. **RESULTS:** We observed national variation of the influence of payers on prescribing decisions. Administrative controls were cited as influencing more than 70% of prescribing decisions in all markets except Germany, where the figure was 50%. Inclusion on formulary was a strong driver of prescriber decisions about therapy, cited as a driver in the majority of individual decision in all markets except Germany. We also observed that prescribers reported that they would have selected an alternative treatment in around 1 in 8 patients, had administrative controls not been in place. Germany was the exception, where this figure is closer to 1 in 20 individual prescribing decisions. **CONCLUSIONS:** This research demonstrates that prescribers' behavior is strongly influenced by administrative controls to which payers contribute, and that there are differences between Germany and the other 4 markets investigated. Further research will establish whether differences reflect actual differences in the nature and impact of controls, or simply greater alignment between prescribers' and payers' objectives or opinions in Germany. This has the potential to inform discussions between prescribers and payers about rational use of medicines and patients' access to medicines.

PCN290

TIERED PRICING IN ONCOLOGY - DRIVERS FOR IMPROVED PATIENT ACCESS AND COMMERCIAL SUCCESS

Favaro A, Saraf S

ICON P&M, London, UK

OBJECTIVES: Tiered pricing, also referred to as differential pricing or equitable pricing, involves adjusting drug prices to the purchasing power of consumers in different geographical or socio-economic segments. Traditionally, tiered pricing strategies have aimed to improve access to medicines in the developing world. There has been increasing interest from manufacturers and payers in employing such strategies for oncology agents, but improved patient access and commercial success has been variable. This research aims to understand the challenges and opportunities associated with implementing tiered pricing for oncology agents and the factors that may contribute to a successful strategy. **METHODS:** Systematically analyse a set of case studies in order to clearly identify current practice and trends in tiered pricing strategies for cancer drugs in key emerging markets. Evaluate various strategies based on publically available information and identify drivers for improved patient access and commercial success. **RESULTS:** Emerging markets represent a complex environment and a number of challenges such as physical and informational arbitrage impact a differential pricing strategy. Strategies driven by short-term profitability objectives have usually failed and those that have not addressed the inefficient distribution channels in emerging markets have also struggled to gain traction. Additionally, a poor knowledge of demand elasticity has often limited impact. **CONCLUSIONS:** Tiered pricing strategies represent a powerful tool for improving patient access to cancer drugs in emerging markets. Every tiered pricing strategy needs to be tailored to each product and market/segment. A clear understanding of the objectives driving the strategy, the potential pricing tools applicable in a market, the distribution channels and methods to mitigate risk are key to improving patient access and supporting commercial success.

PCN291

BUILDING A REAL WORLD DATA NETWORK TO SUPPORT ACCESS TO ONCOLOGY MEDICINES IN FRANCE: THE PERSONALISED REIMBURSEMENT MODELS INITIATIVE

Cogez F, Rose M, Taraud O, Pinguet J

Roche SAS, Boulogne-Billancourt, France

OBJECTIVES: Oncology medicines reimbursed in France have a fixed price whereas the benefits vary across patient groups. Pricing models aligned to the benefit for patients open an interesting concept, but they need to be supported by reliable and standardised metrics aligned with health authorities' expectation. The Personalised Reimbursement Models (PRM) pilots aim to establish an infrastructure validated by the National Data Privacy Committee to collect existing data of metastatic breast cancer patients (mBC) taking trastuzumab and leverage preliminary analytics to evaluate the relevance of this approach. **METHODS:** mBC patients at 14 pilots centres recorded in the Electronic Pharmacy Record (EPR) system with at least one trastuzumab claim between January 2011 to October 2014 that were not enrolled in a clinical trial were selected. Data related to demographics, disease description, drug usage and clinical outcomes were collected in the EPR. These data were controlled, cleaned and centralised in an anonymous and secure way through an accredited hosting provider. **RESULTS:** 510 mBC patients taking trastuzumab were identified. 21 of the 30 target variables were available in the EPR with a mean of 3.5% percent of missing data and results that were consistent with literature. Unavailable variables have been identified in other data sources within centres or could be added to the EPR by updating and enhancing the health information systems. The recruitment of around 100 additional centres began in January 2015 following a sampling method designed to ensure the representativeness of clinical practice. **CONCLUSIONS:** Pilot study has validated technical and legal feasibility of the PRM infrastructure implementation and the quality of the outputs. Over time, PRM will deliver robust and standardised real world evidence that could be used to implement models that will support more flexible pricing strategies and help ensure patient access to innovative treatments delivered in different indications.

PCN292

ASSESSING THE GAP BETWEEN EVIDENCE BASED INDICATIONS FOR RADIOTHERAPY AND ACTUAL PRACTICE IN EUROPEAN COUNTRIES

Borras JM¹, Dunscombe P², Barton M³, Gasparotto C⁴, Defourny N⁴, Grau C⁵, Lievens Y⁶